On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
21 juin 2024 16h04 HE
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
11 juin 2024 08h44 HE
|
NurExone Biologic Inc
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations
17 mai 2024 16h04 HE
|
NurExone Biologic Inc
NurExone Welcomes Biopharma Executive Dr. Ram Petter to Drive Strategic Collaborations
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
25 avr. 2024 08h35 HE
|
NurExone Biologic Inc
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
22 avr. 2024 08h00 HE
|
Elevai Labs Inc.
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market
18 mars 2024 08h30 HE
|
Elevai Labs Inc.
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel
08 mars 2024 16h05 HE
|
NurExone Biologic Inc
NurExone establishing State-of-the-Art Research and Development Facility on Technion Campus in Israel
NurExone’s Intellectual Property Portfolio Expands
20 févr. 2024 16h05 HE
|
NurExone Biologic Inc
NurExone's Intellectual Property portfolio is expanding to encompass processes and compositions related to exosomes in large-scale production
NurExone Launches Licensing Efforts for ExoTherapy Platform
14 févr. 2024 16h20 HE
|
NurExone Biologic Inc
NurExone Biologic launches licensing efforts for its ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
02 févr. 2024 16h05 HE
|
NurExone Biologic Inc
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant for its groundbreaking ExoPTEN product